Company’s 36-month beta value is 1.13.Analysts have differing opinions on the stock, with 3 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for MNPR is 3.05M, and currently, short sellers hold a 2.36% ratio of that floaft. The average trading volume of MNPR on November 14, 2024 was 1.25M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
MNPR) stock’s latest price update
The stock of Monopar Therapeutics Inc (NASDAQ: MNPR) has increased by 11.48 when compared to last closing price of 17.25.Despite this, the company has seen a gain of 21.86% in its stock price over the last five trading days. globenewswire.com reported 2024-11-08 that In-licensed ALXN-1840 (a Late-Stage Wilson Disease Drug Candidate) from Alexion, AstraZeneca Rare Disease Two Novel Radiopharma Clinical Trials now Active and Enrolling Patients with Advanced Solid Cancers
MNPR’s Market Performance
Monopar Therapeutics Inc (MNPR) has seen a 21.86% rise in stock performance for the week, with a 273.40% gain in the past month and a 711.39% surge in the past quarter. The volatility ratio for the week is 10.55%, and the volatility levels for the past 30 days are at 48.87% for MNPR. The simple moving average for the past 20 days is 33.50% for MNPR’s stock, with a 314.96% simple moving average for the past 200 days.
Analysts’ Opinion of MNPR
Many brokerage firms have already submitted their reports for MNPR stocks, with Rodman & Renshaw repeating the rating for MNPR by listing it as a “Buy.” The predicted price for MNPR in the upcoming period, according to Rodman & Renshaw is $50 based on the research report published on October 11, 2024 of the current year 2024.
ROTH Capital, on the other hand, stated in their research note that they expect to see MNPR reach a price target of $49. The rating they have provided for MNPR stocks is “Buy” according to the report published on January 28th, 2021.
MNPR Trading at 126.96% from the 50-Day Moving Average
After a stumble in the market that brought MNPR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -50.05% of loss for the given period.
Volatility was left at 48.87%, however, over the last 30 days, the volatility rate increased by 10.55%, as shares surge +265.59% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +688.11% upper at present.
During the last 5 trading sessions, MNPR rose by +21.86%, which changed the moving average for the period of 200-days by +920.70% in comparison to the 20-day moving average, which settled at $14.40. In addition, Monopar Therapeutics Inc saw 1030.51% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MNPR starting from Radhakrishnan Karthik, who purchase 1,550 shares at the price of $16.25 back on Oct 28 ’24. After this action, Radhakrishnan Karthik now owns 1,550 shares of Monopar Therapeutics Inc, valued at $25,188 using the latest closing price.
Cittadine Andrew, the Chief Operating Officer of Monopar Therapeutics Inc, purchase 20,508 shares at $0.74 during a trade that took place back on Jun 20 ’24, which means that Cittadine Andrew is holding 186,132 shares at $15,254 based on the most recent closing price.
Stock Fundamentals for MNPR
The total capital return value is set at -0.26. Equity return is now at value -112.04, with -88.32 for asset returns.
Currently, EBITDA for the company is 0.43 million with net debt to EBITDA at 3.82. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.41.
Conclusion
In a nutshell, Monopar Therapeutics Inc (MNPR) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
